Method of treating arrhythmias
AssigneeCV Therapeutics, Inc.
InventorsLuiz Belardinelli, Arvinder Dhalla
Life of this patent
Estimating the term…
Abstract
Methods are provided for treating arrhythmia in a manner that minimizes undesirable side effects, comprising administration of a therapeutically effective minimal dose of an A1 adenosine receptor agonist with a therapeutically effective minimal dose of a beta blocker, calcium channel blocker, or a cardiac glycoside.
Claims5
A pharmaceutical composition comprising a synergistic therapeutically effective minimal dose of an A1 adenosine receptor agonist of Formula I and a therapeutically effective minimal dose of a beta blocker, and at least one pharmaceutically acceptable excipient, wherein the A1 adenosine receptor agonist is a compound of Formula I:
- wherein R1 is 3-(R)-tetrahydrofuranyl,
- wherein the beta blocker is esmolol, and
- wherein the therapeutically effective amount of the compound of Formula I is from about 0.5 to 20 μg/kg and the therapeutically effective amount of esmolol is from about 0.1 to 10 mg/kg.
A pharmaceutical composition comprising a synergistic therapeutically effective minimal dose of an A1 adenosine receptor agonist of Formula I and a therapeutically effective minimal dose of a beta blocker, and at least one pharmaceutically acceptable excipient, wherein the A1 adenosine receptor agonist is a compound of Formula I:
- wherein R1 is 3-(R)-tetrahydrofuranyl,
- wherein the beta blocker is metoprolol, and
- wherein the therapeutically effective amount of the compound of Formula I is from about 0.5 to 20 μg/kg and the therapeutically effective amount of metoprolol is from about 0.1 to 10 mg/kg.
A pharmaceutical composition comprising a synergistic therapeutically effective minimal dose of an A1 adenosine receptor agonist of Formula II and a therapeutically effective minimal dose of a beta blocker, and at least one pharmaceutically acceptable excipient, wherein the A1 adenosine receptor agonist is a compound of Formula II:
- wherein R1 is (R)-2-hydroxycyclopentyl, X and Y are covalent bonds, R2, R4, and R5 are hydrogen, and R3 is 2-fluorophenyl, namely 2-{6-[((1R,2R)-2-hydroxycyclo-pentyl)amino]purin-9-yl}(4S,5S,3R)-5-[(2-fluorophenylthio)methyl]oxolane-3,4-diol (CVT-3619),
- wherein the beta blocker is esmolol, and
- wherein the therapeutically effective amount of the compound of Formula II is from about 0.1 to 200 mg/kg and the therapeutically effective amount of esmolol from about 0.01 to 100 mg/kg.
A pharmaceutical composition comprising a synergistic therapeutically effective minimal dose of an A1 adenosine receptor agonist of Formula II and a therapeutically effective minimal dose of a beta blocker, and at least one pharmaceutically acceptable excipient, wherein the A1 adenosine receptor agonist is a compound of Formula II:
- wherein R1 is (R)-2-hydroxycyclopentyl, X and Y are covalent bonds, R2, R4, and R5 are hydrogen, and R3 is 2-fluorophenyl, namely 2-{6-[((1R,2R)-2-hydroxycyclo-pentyl)amino]purin-9-yl}(4S,5S ,3R)-5-[(2-fluorophenylthio)methyl]oxolane-3,4-diol (CVT-3619),
- wherein the beta blocker is metoprolol, and
- wherein the therapeutically effective amount of the compound of Formula II is from about 0.1 to 200 mg/kg and the therapeutically effective amount of metoprolol from about 0.01 to 100 mg/kg.
A pharmaceutical composition comprising a synergistic therapeutically effective minimal dose of an A1 adenosine receptor agonist of Formula II and a therapeutically effective minimal dose of a beta blocker, and at least one pharmaceutically acceptable excipient, wherein the A1 adenosine receptor agonist is a compound of Formula II:
- wherein R1 is (R)-2-hydroxycyclopentyl, X and Y are covalent bonds, R2, R4, and R5 are hydrogen, and R3 is 2-fluorophenyl, namely 2-{6-[((1R,2R)-2-hydroxycyclo-pentyl)amino]purin-9-yl}(4S ,5S,3R)-5-[(2-fluorophenylthio)methyl]oxolane-3,4-diol (CVT-3619),
- wherein the beta blocker is propranolol, and
- wherein the therapeutically effective amount of the compound of Formula II is from about 0.1 to 200 mg/kg and the therapeutically effective amount of propranolol from about 0.01 to 100 mg/kg.
Dependencies are inferred from the claim text.